This indicates that Kynamro is barely getting any traction with less than $10M of sales in 2013
$48.5M in 2013 sales for Juxtapid, so far undisclosed sales for ISIS Kynamro. Will this non-oral antisense molecule get better uptake than Juxtapid among docs? We will know tomorrow...
Am trying to understand how projected revenues for their lead drug justify their current valuation. if anyone has thoughts on how much revenue their lead drug can generate this year please share
Doesn't matter what happens tomorrow. They sold calls at the market bid price, averaging around $0.80/share. This options play is a bet that the price will be less than $18.30 by March 22.
Agreed this is worrisome. No mention of meeting primary endpoint and they talked nicely around that key point.
Large number of March 17.50 calls were sold at the bid this morning. Was well above open interest meaning they were sold to open the position. Big bet that RPTP will be down from current positions.
Lots of whispers at JPM conference today about much better than expected sales coming out shortly that has driven some of the big companies into talks with IMGN